Concord Drugs Limited Announces Results for the Third Quarter and Nine Months Ended December 31, 2024

Concord Drugs Limited has reported its results for the third quarter and nine months ended December 31, 2024. For the third quarter, the company reported revenue of 107.99 million Indian rupees, compared to 127.84 million Indian rupees a year ago. The turnover stood at INR 107.99 million, compared to INR 12,783.7 million in the previous year. The net profit was 2.27 million Indian rupees, compared to a net loss of 2.41 million Indian rupees the previous year. Basic earnings per share from continuing operations was INR 0.23, compared to basic loss per share from continuing operations of INR 0.24 a year ago. Diluted earnings per share from continuing operations was INR 0.23, compared to diluted loss per share from continuing operations of INR 0.24 a year ago.
For the nine months, revenue stood at INR 348.53 million, compared to INR 292.82 million in the previous year. The turnover stood at INR 348.63 million compared to INR 292.9 million a year ago. The net profit was INR 2.97 million compared to INR 8.11 million in the previous year. Basic earnings per share from continuing operations was INR 0.3, compared to INR 0.81 in the previous year. Diluted earnings per share from continuing operations was INR 0.3, compared to INR 0.81 in the previous year.